Novel Treatment for Staphylococcal Aureus Infections Shows Promising Results, Says La Merie Publishing

22 May 2012 • by Natalie Aster

Staphylococcal aureus infections represent an enormous burden to public health systems. Traditionally restricted to the hospital setting as nosocomial infections, highly virulent strains have recently emerged in outside healthcare settings. Together with the increasing resistance to many antibacterials in a wide variety of staphylococcal strains, development of vaccines or specific and potent therapies for staphylococcal diseases raised increasing interest.

Finding a vaccine for staphylococci is not trivial, as protective immunity to staphylococcal infections does not appear to exist at a significant degree. Promising results from novel approaches based on the combination of systematically selected antigens have been reported.

The most recent report “Competitor Analysis: Staphylococcus Aureus Vaccines and Therapeutics” by La Merie Publishing includes a compilation of currently active projects in research and development of antibodies, proteins, peptides, vaccines and small molecules for prevention and treatment of Staphylococcus aureus infections. In addition, the study lists company-specific R&D pipelines of S. aureus vaccines and therapeutics. Competitor projects are listed in a tabular format providing information on:

  • drug codes; 
  • target / mechanism of action; 
  • class of compound; 
  • company; 
  • product category; 
  • indication; 
  • R&D stage; 
  • additional comments with a hyperlink leading to the source of information.

Report Details:

Competitor Analysis: Staphylococcus Aureus Vaccines and Therapeutic
Published: May, 2012
Pages: 45
Price: US$ 394,00

Passive immunotherapy with monoclonal therapeutic antibodies against S.aureus is another means to approach specific therapy of staphylococcal. While anti-staphylococcal purified polyclonal immunoglobulins are not recommended for prevention of staphylococcal infections in preterm or VLBW neonates, monoclonal antibodies are currently emerging and are in early development. Although not specific, bactericidal proteins and peptides with activity against S. aureus are in preclinical and clinical development. More targeted and improved antibiotics are also in development.

More information can be found in the report “Competitor Analysis: Staphylococcus Aureus Vaccines and Therapeutic” by La Merie Publishing.

To order the report or ask for sample pages contact


MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970